Genoma is being sued by Illumina over four patents covering technology for prenatal testing, that uses NGS to diagnose fetal defects.
After suing Oxford Nanopore over porin technology, Illumina is back to another contentious field – their patents for a type of non-invasive prenatal testing (NIPT).
Illumina has filed a patent infringement suit in the Federal Patent Court in Switzerland, against Genoma – a diagnostics provider based in Geneva (Switzerland).
Genoma’s pre-natal test Tranquility allegedly uses Illumina’s intellectual property, protected by 4 different European patents: (CH) 2 183 693 B1, (CH) 0 994 963 B2, (CH) 1 981 995 B1, and (CH) 2 514 842.
The lawsuit against Genoma traces back to Premaitha’s IONA test, which was the target of another lawsuit from Illumina in March 2015. Genoma’s test is based on IONA.
This content is available exclusively to our paying members.
Our members receive the following benefits:
- Unlock premium articles
- Download our industry reports
- Remove all banner ads
- Access 1,500+ archived posts
- Support our independent media